US0311621009 - Common Stock
AMGEN INC
NASDAQ:AMGN (11/4/2024, 8:00:00 PM)
After market: 317.1 +0.19 (+0.06%)316.91
-2.31 (-0.72%)
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 26,700 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. The company operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA 91320
P: 18054471000
CEO: Robert A. Bradway
Employees: 26700
Website: https://www.amgen.com/
The major indexes declined, but haven't fallen apart.
AMGN earnings call for the period ending September 30, 2024.
The company expects to have topline results from a Phase 2 study later this year.
Amgen Inc.’s third-quarter profit beat Wall Street estimates as the company’s expenses were lower than anticipated.
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. "Strong growth in sales and earnings this quarter reflects...
Here you can normally see the latest stock twits on AMGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: